Quant Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
- September 18, 2026
- Posted by: Chaitanya Auti
- Category: Mutual Funds
Quant Healthcare Fund Direct Growth Plan currently has a NAV of ₹19.1917 as of 17 Sep 2026 and an AUM of ₹428 Cr. Its 1-year, 3-year and 5-year returns are 17.78%, 19.87% and 0% respectively, and the scheme sits in the High Risk category. Our view is that it suits investors who can tolerate sharp swings and want sector-led equity exposure, but the weak short-term benchmark comparison means the recent run has been uneven even though the longer 3-year trend remains positive.
The fund is concentrated in healthcare names and its largest holdings account for a substantial share of the portfolio, so stock selection matters. That makes it more suitable for investors with a longer horizon who can accept periods when returns trail the broader market before the sector’s own cycle supports performance again.
Quick facts
| Particular | Details |
|---|---|
| NAV | ₹19.1917 as of 17 Sep 2026 |
| AUM | ₹428 Cr |
| Expense Ratio | 0.8% |
| Launch Date | 17 Jul 2023 |
| Min SIP | ₹1,000 |
| Risk Category | High Risk |
| Benchmark | Nifty 50 |
| Fund Category | Equity |
| Exit Load | 1% on or before 15D, Nil after 15D |
| Fund Managers | Sandeep Tandon, Ankit Pande, Varun Pattani, Ayusha Kumbhat |
The fund is managed by Sandeep Tandon, Ankit Pande, Varun Pattani and Ayusha Kumbhat.
Source data date: as of 17 Sep 2026
Performance
| Period | Fund return | Benchmark return |
|---|---|---|
| 1M | 1.12% | -3.66% |
| 3M | 10.48% | -3.71% |
| 1Y | 17.78% | -7.13% |
| 3Y | 19.87% | 5.82% |
| 5Y | Data not available | Data not available |
The fund’s short-term showing has improved, especially over 1 month and 3 months, where it stayed positive while the benchmark was negative. That tells us the portfolio has recently benefited from sector-specific strength rather than broad market support. The 1-year return is also comfortably positive at 17.78%, which is a meaningful contrast with the benchmark’s -7.13% over the same period.
The 3-year picture is still constructive at 19.87%, but it also shows that the fund’s path has not been smooth. The 3-year return is well above the benchmark’s 5.82%, yet the month-to-month trend in the underlying movement shows visible drawdowns and recoveries, which is typical of a concentrated thematic equity fund. That means gains have come with noticeable swings along the way.
For a fund launched in July 2023, the 5-year row is not available in a practical sense, so the more useful lens is how the 1-year and 3-year numbers line up. The latest phase looks stronger than the benchmark, but the longer-run pattern still suggests this is a higher-variance fund rather than a steady market proxy.
Source data date: as of 17 Sep 2026
Should you BUY or HOLD Quant Healthcare?
A fund’s past returns alone don’t tell you whether you should buy it today or continue holding it.
The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.
Already holding Quant Healthcare? Thinking of investing now?
Peer comparison
| Fund | 1Y return | 3Y return | 5Y return |
|---|---|---|---|
| Quant Healthcare Fund Direct Growth Plan | 17.78% | 19.87% | Data not available |
| ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan | 69.8% | 36.32% | Data not available |
| HDFC Pharma and Healthcare Fund Direct Growth Plan | 25.31% | Data not available | Data not available |
| Kotak Healthcare Fund Direct Growth Plan | 25.27% | Data not available | Data not available |
| Motilal Oswal Active Momentum Fund Direct Growth Plan | 24.51% | Data not available | Data not available |
| PGIM India Healthcare Fund Direct Growth Plan | 22.75% | Data not available | Data not available |
This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639.
On the recent 1-year measure, the fund trails the stronger peer figures in this set, especially the sharp numbers posted by the metal-and-energy fund and the stronger healthcare peers. That suggests the latest stretch has been decent but not exceptional versus the names shown here.
The 3-year comparison is more balanced because only one peer in the table has a usable 3-year figure, and that peer is ahead. Even so, this fund’s 19.87% over 3 years still shows a solid compounding profile. The short-term and longer-term pictures therefore do not tell the same story: the recent pace has been respectable, while the multi-year outcome remains more moderate than the strongest peer figure available.
Source data date: as of 17 Sep 2026
Want to know more? Log in to Univest for more mutual fund insights.
Portfolio: where your money goes
| Holding | Sector | Weight |
|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | 10.58% |
| Glenmark Pharmaceuticals Ltd 29/09/2026 | Healthcare | 9.83% |
| Divi’S Laboratories Limited 29/09/2026 | Healthcare | 9.46% |
| Zydus Lifesciences Limited | Healthcare | 9.3% |
| Pfizer Ltd | Healthcare | 8.83% |
| Alivus Life Sciences | Healthcare | 8.08% |
| Torrent Pharmaceuticals Ltd 29/09/2026 | Healthcare | 7.87% |
| Concord Biotech Limited | Healthcare | 7.03% |
| SMS Pharmaceuticals Limited | Healthcare | 6.71% |
| Ipca Laboratories Ltd | Healthcare | 6.22% |
The largest holding is Glaxosmithkline Pharmaceuticals Ltd at 10.58%, which is large enough to matter but not so large that one position alone defines the fund. The weight then steps down gradually, with the tenth holding still above 6%, so influence is spread across several names rather than concentrated in just one stock.
The top 10 holdings together account for approximately 83.91% of the portfolio, which means the disclosed part of the portfolio is fairly concentrated. Because the fund has 22 disclosed holdings in total, the visible book may still have a meaningful tail beyond the top positions, but the published allocation suggests that a relatively small group of healthcare companies is likely to have greater influence on returns.
That concentration can help when the selected healthcare names move in the same direction, but it can also amplify slippage if the sector or a few large positions weaken. For investors, the key point is that this is not a broad diversified equity basket; it is a focused sector fund where stock selection and sector conditions can matter a great deal.
To see all holdings, visit the Quant Healthcare Fund Direct Growth Plan page
Source data date: as of 17 Sep 2026
Who should invest
This fund fits investors who are comfortable with High Risk and who can hold through uneven periods. The return pattern shows a stronger 1-year and 3-year outcome than the benchmark, but it also shows that the ride can be choppy, which is typical of a concentrated sector strategy.
A longer horizon is more suitable here because the fund’s performance can depend heavily on healthcare-sector sentiment and on a handful of large holdings. The main trade-off is simple: you get focused exposure to a specific equity theme, but you must accept that it may lag the broader market when the sector is out of favour.
Tax and exit load
| Holding period | Tax rate | Description |
|---|---|---|
| Units held less than 1 year | 20% | Short-term capital gains tax |
| Units held more than 1 year | 12.5% | Long-term capital gains tax |
Exit load: 1% on or before 15D, Nil after 15D.
Source data date: as of 17 Sep 2026
Frequently asked questions
What is the current NAV of Quant Healthcare Fund Direct Growth Plan?
It is ₹19.1917 as of 17 Sep 2026.
What are the fund’s 1-year, 3-year and 5-year returns?
The returns are 17.78% for 1 year, 19.87% for 3 years and Data not available for 5 years.
How does the fund compare with its benchmark?
It has outpaced the Nifty 50 over 1 month, 3 months, 1 year and 3 years. The benchmark was negative over the shorter windows and positive over 3 years, while the fund stayed ahead in each of those periods.
How does it compare with the peer funds shown here?
Its 1-year return is below the stronger peer figures shown, while its 3-year return is also below the available 3-year peer figure. That makes the recent and multi-year peer picture less strong than the leading names in this set.
What is the minimum SIP amount?
The minimum SIP amount is ₹1,000.
Who manages the fund and what is the exit load?
The fund is managed by Sandeep Tandon, Ankit Pande, Varun Pattani and Ayusha Kumbhat. The exit load is 1% on or before 15D, and Nil after 15D.
Bottom line
Quant Healthcare Fund Direct Growth Plan has a stronger recent and 3-year record than the broad benchmark, but the path has been uneven and the fund remains clearly High Risk. Against the peer names shown here, its 1-year and 3-year returns are not the strongest available, which puts it in the middle of a competitive healthcare-themed field rather than at the front of it. The portfolio is concentrated in healthcare stocks, so sector conditions and individual stock calls are likely to matter more than in a diversified equity fund.
Published on 18 September 2026 at 1:56 PM IST
Explore mutual funds with Univest
Review mutual fund data, compare performance and explore fund insights on Univest.
RIA disclosure
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.